Article

Pseudoaccommodative IOL offers excellent range of vision

Refractive lens exchange with implantation of the Acrysof ReSTOR IOL (Alcon Laboratories) is an effective method for providing an excellent range of vision for presbyopic myopes or hyperopes, said Francesco Carones, MD, at the refractive surgery subspecialty day meeting.

New Orleans-Refractive lens exchange with implantation of the Acrysof ReSTOR IOL (Alcon Laboratories) is an effective method for providing an excellent range of vision for presbyopic myopes or hyperopes, said Francesco Carones, MD, at the refractive surgery subspecialty day meeting.

Dr. Carones, a private practitioner in Milan, Italy, reported results from a prospective, consecutive, interventional case series involving 30 eyes of 15 patients aged 44 to 65 years old. The cohort included 12 hyperopes (+1.25 to +3.25 D) and 3 myopes (-1.25 to -3.75 D) who underwent clear lens exchange through a 2.8-mm clear corneal temporal tunnel incision.

After 6 months, all eyes were within ±0.620 D SE, had 20/25 or better distance UCVA and J2 or better near UCVA. In 14 patients, intermediate UCVA was J4 or better.

BSCVA was stable, and wavefront studies showed there were no significant changes in higher-order aberrations. None of the patients experienced unwanted visual symptoms in bright light nor did any have significant symptoms at night, although two individuals reported slight rings around lights.

Overall, the patients rated themselves as extremely satisfied with their near vision and their satisfaction with their intermediate vision was relatively good.

"This is a small series with a short follow-up, but the results are positive so far. Patients achieved immediate, stable improvement across the full range in vision, side effects have been negligible, and satisfaction high. Based on these findings, we believe refractive lens exchange with implantation of this pseudoaccommodative IOL may be an important solution to correcting defocus and presbyopia in the future," Dr. Carones said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.